Honeywell Quantum Solutions, Cambridge Quantum Computing To Merge

Honeywell Quantum Solutions and Cambridge Quantum Computing will merge to form the largest, most advanced standalone quantum computing company in the world, Honeywell (HON) said in a statement.

Honeywell noted that the new company will offer highest performing quantum computer and a full suite of quantum software, including the first and most advanced quantum operating system. The new company will shape the future of what is projected to become a $1 trillion quantum computing industry over the next three decades.

Upon completion of the combination, Honeywell will own a majority stake of the new company, with commensurate governance rights. In addition, Honeywell will invest between $270 million and $300 million in the new company and will have a long-term agreement to help manufacture the critical ion traps needed to power the quantum hardware.

The merger is expected to be complete in the third quarter of 2021. Honeywell Chairman and Chief Executive Officer Darius Adamczyk will serve as chairman of the new company. The new company will be led by Ilyas Khan, the CEO and founder of Cambridge Quantum Computing. Tony Uttley, currently the president of Honeywell Quantum Solutions, will serve as the new company's president.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT